Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...

based WVU Cancer Institute has become the first in the world to commercially use a new, FDA-approved medical device designed to lower the risk of esophageal cancer. Led by Shyam Thakkar ...

Connolly, who represents a swath of Northern Virginia, easily won reelection to a ninth term in the House this week.

Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with ...

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...

Esophageal Catheters Market. The global esophageal catheters market is poised for significant expansion, with a projected market value of USD 2.2 billion in 2022, and a robust com ...

has been diagnosed with esophageal cancer. Connolly, as reported by The Washington Post, said Thursday morning he will ...

It's known as EOE - Eosinophilic Esophagitis. For more than 30 years ... Other signs include heartburn that doesn't respond to treatment. "Sometimes it could be chest pain or regurgitation ...

We are pleased that research continues and offers new treatment options to improve the quality of their care.” “Eosinophilic esophagitis presents a unique challenge in young children ...

Young-Onset Barrett's Esophagus Incidence on the Rise The incidence of ... which persists over time" and "is correlated with ...

Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...

Sanofi “Up to half of all children in the EU with eosinophilic esophagitis remain uncontrolled despite existing standard of care treatment options, and, as a result, many of these young patients ...